Baxalta launches U.S. availability of hemophilia A treatment ADYNOVATE Baxalta (BXLT) announced the launch and first shipments of ADYNOVATE, an extended circulating half-life recombinant factor VIII treatment for hemophilia A based on full-length ADVATE. The treatment was approved by the U.S. Food and Drug Administration in November. "Patients living with hemophilia are increasingly looking for and need treatment options that can address their individual needs," said Dr. Michael Tarantino, medical director of the Bleeding & Clotting Disorders Institute. "The simplicity of ADYNOVATE's twice weekly dosing schedule offers an important new option for the hemophilia community, delivering first and foremost on what matters most - bleed protection, while also easing the schedule of their prophylactic treatment." ADYNOVATE was developed through a collaboration with Nektar Therapeutics (NKTR).